Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. on December 16, 2005. The filing discloses the entry into material definitive employment agreements with key executive officers and a subsidiary executive.
Key Financial Metrics
The filing does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.
- COO Base Salary: $235,000 annually (Susan M. Luscinski).
- CFO Base Salary: $175,000 annually (Bryce Chicoyne).
Material Changes
On December 16, 2005, the Company executed new employment agreements for its Chief Operating Officer and Chief Financial Officer. Additionally, Union Biometrica, Inc., a subsidiary within the Capital Equipment Business Segment, entered into a letter agreement with its president, David Strack, regarding change of control provisions.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, outlook, or management commentary regarding future financial performance. Key contractual terms and contingencies include:
- Term: Agreements are for one year with automatic annual renewal unless 90 days' notice is given.
- Non-Compete: Executives are restricted from competing or soliciting employees for 12 months post-termination.
- Termination Benefits: In cases of termination without cause or for good reason, executives are eligible for up to one year's salary and bonus, one year of benefit extension, and acceleration of vesting for stock options/restricted stock vesting within the next 12 months.
- Change of Control: Triggers payment of up to one year's salary and bonus, benefit extension, and full acceleration of all outstanding stock options and restricted stock.
- Subsidiary Provisions: David Strack's agreement requires six months' notice for termination without cause within 12 months of a change of control and immediate vesting of all options upon such change.
Investor Verification Checklist
- Verify the total equity grant value associated with the accelerated vesting provisions described.
- Confirm the current status of the Capital Equipment Business Segment and Union Biometrica, Inc.
- Review the Compensation Committee's annual salary re-determination process for future cost implications.
- Assess the potential cash outflow impact if a change of control or termination without cause occurs.